Please login to the form below

Not currently logged in
Email:
Password:

Sarepta Therapeutics

This page shows the latest Sarepta Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Sarepta is to deepen its presence in gene therapy with a new licensing deal with Lacerta Therapeutics. ... Sarepta has made its name by launching the first ever FDA approved treatment for Duchenne muscular dystrophy, Exondys 51, and is now looking to

Latest news

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    Pfizer, Roche and PTC Therapeutics are among those participating in Project Hercules. ... The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life Sciences - all have an interest in DMD as well as other rare and orphan

  • FDA approves first steroid for Duchenne muscular dystrophy FDA approves first steroid for Duchenne muscular dystrophy

    The agency granted orphan and priority review status for the drug, which is the second DMD treatment to be approved in the US after Sarepta Therapeutics' exon-skipping therapy Exondys 51

  • Sarepta soars as FDA clears its muscular dystrophy drug Sarepta soars as FDA clears its muscular dystrophy drug

    Sarepta shares closed up 74% yesterday after news of the conditional approval for Exondys 51 (eteplirsen) broke - taking investors by surprise. ... Earlier this year, Sarepta Therapeutics told Muscular Dystrophy UK that they plan to apply to the EMA by

  • FDA panel rejects BioMarin's muscular dystrophy drug FDA panel rejects BioMarin's muscular dystrophy drug

    A rival therapy from Sarepta Therapeutics called eteplirsen, which has a similar 'exon-skipping' mode of action to drisapersen, is due to come in front of the advisory committee in January, ... Sarepta is seeking approval of eteplirsen with a smaller

  • Sarepta seeks new CEO but says eteplirsen is on track Sarepta seeks new CEO but says eteplirsen is on track

    Garabedian will be temporarily replaced by CMO Ed Kaye.  . Sarepta Therapeutics' chief executive Chris Garabedian has stepped down just as its lead drug for Duchenne muscular dystrophy (DMD) is about to ... PTC Therapeutics' Translarna (ataluren) - is

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics. ... Licence. 145. Sarepta Therapeutics/  Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Prosensa has just begun a rolling submission of the application. BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in ... This month also saw CAR-T “wunder-kid” Juno Therapeutics

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Minoryx Therapeutics adds to board of directors Minoryx Therapeutics adds to board of directors

    Dr Claude Nicaise joins as an independent board member. Dr Claude Nicaise has joined Barcelona, Spain-based Minoryx Therapeutics as an independent board member. ... He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • W2O Group

    Sanofi. Bayer. Sarepta Therapeutics.

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics. ... Procter &Gamble. Reckitt Benckiser. Regeneron. Replicel. Roche. RPS. Sanofi. Santen. Sarepta Therapeutics.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics